
Hypoxia-induced IncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/ KRAS pathway


Supplementary Materials

Location Chromosome 9: 77.580.245-77.580.628 forward strand. About this transcript This transcript that 1 exon and maps to 1 oligo probe. Gene This transcript is a product of gene ENSG00000228248 Hide transcript table Show/hide columns Filter Name Transcript ID bp Protein Translation ID Biotype CCDS NUTF2P3-001 ENST00000448540 384 No protein Processed pseudogene ATGGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	About this transcript This transcript has 1 exon and maps to 1 oligo probe. Gene This transcript is a product of gene ENSG00000228248 Hide transcript table Show/hide columns Filter Name Transcript ID bp Protein Translation ID Biotype CCDS Flag NUTF2P3-001 ENST00000448540 384 No protein I Processed pseudogene TSL:NA GE ATGGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	transcript		port factor 2 pseudo	ogene 3 [Source:HGNC S	Symbol;Acc:H	GNC:50452	
Gene This transcript is a product of gene ENSG00000228248 Hide transcript table Show/hide columns Filter Name Transcript ID bp Protein Translation ID Biotype CDS Flags NUTF2P3-001 ENST00000448540 384 No protein - Processed pseudogene - TSLNA GENCODE bas ATGGGAGATAAGCTGATTTGGGAAGCAAACTGAATCCAGCTTCATTCA	Gene This transcript is a product of gene ENSG00000228248 Hide transcript table Show/hide columns Filter Name © Transcript ID © bp © Protein © Translation ID © Biotype © CCDS © Flag NUTF2P3-001 ENST00000448540 384 No protein © Translation ID © Biotype © CCDS © Flag NUTF2P3-001 ENST00000448540 384 No protein I Processed pseudogene TSL:NA GE ATGGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCGTCATGCCTTAGGGTGGGGAAGGACA GGGGAAAGCTGCCATTGGGGAAGGTACAATTTACATTGACGCGGTCATGCCTTAGGGTGGGGAAGGACA GGGGAAAGCTGCCATTGTGGAGAAGTTGTCTAGCCTTCTGTTCCAGAAAATCCAGTACAGC ACAGGACAATTAGCCCACACCAGATAGCTGCATCATCAGCATGGTTGTGGGGTGAGCTTAAGC GACCCCATCATCGGGTTCCACCAGATAGCTGCATCATCAGCATGGTTGTGGGGTGAGCTTAAGC GACCCCATCATCGGGTTCCCACCAGATAGCTGCATCCTATTAAAGAATATCAGTGAAGCTTGGGTTA GACCCCATCATCGGGTTCCACCAGATGGTTCCTATTAAAGAATATCAGTGAAGCTTGGGTTT	transcript	Chromosome	e 9: 77,580,245-77,5	580,628 forward strand.	-	-	
This transcript is a product of gene ENSG00000222243 Titler Show/hide columns Filter NUTF2P3-001 ENST00000448540 384 No protein Processed pseudogene CDS Flags ATGGGAGATAAGCTGAATTTGGAAGCAAACTGAATCCAGCTTCATTCA	This transcript is a product of gene ENSIG00000228248 Hide transcript table Show/hide columns Filter Nutre transcript ID to bp to Protein to Translation ID to Biotype to CCDS to	transoript	This transcrip	ot has 1 exon and m	aps to 1 oligo probe.			
Name Transcript ID bp Protein Translation ID Biotype CCDS Flags NUTF2P3-001 ENST00000448540 384 No protein - Processed pseudogene - TSL:NA GENCODE bas ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	Name Transcript ID bp Protein Translation ID Biotype CCDS Flag NUTF2P3-001 ENST00000448540 384 No protein I Processed pseudogene TSL:NA GE ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGGCTCATTCAACATTACTACCAGT AGATACAACCCGAATAGGTACAATTTACATTGACGCGGTCATGCCTTAGGTGGGGAAGGACA GGGGAAAGCTGCCATTGTGGGAGAAGTTGTCTAGCCTTCGTTCCAGAAAATCCAGTACAGC AGAGGACAATTAGCCCACACCAGATAGCTGCATCATCAGCATGGTTGTGGGGTGAGCTTAAG GGGGAAAGCTGCCATCGGGGTCCACCCAGATAGCTGCATCATCAGCATGGTTGTGGGGTGAGCTTAAG GGGCCCCATCATCGGGTTCCCACCAGATGTCCTATTAAAGAATATCAGTGAAGCTTGGGTTG GGGGTTGTCCACCAGGTTGTCCTATTAAAGAATATCAGTGAAGCTTGGGTTGT		This transcrip	pt is a product of ge	ne ENSG00000228248	Hide transcri	ot table	
Name Transcript ID bp Protein Translation ID Biotype CCDS Flags NUTF2P3-001 ENST00000448540 384 No protein - I Processed pseudogene - TSL:NA GENCODE bas ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	Name Transcript ID bp Protein Translation ID Biotype CCDS Flag NUTF2P3-001 ENST00000448540 384 No protein I Processed pseudogene TSL:NA GE ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGGCTTCATTCA							
NUTF2P3-001 ENST00000448540 384 No protein - Processed pseudogene - TSLNA GENCODE bas ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	NUTF2P3-001 ENST00000448540 384 No protein I Processed pseudogene TSL:NA GE ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA							
ATGGGAAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	ATGGGAGATAAGCTGATTTGGAAGCAAACTGAATCCAGCTTCATTCA	•				· ·		
AAGATACAACCCGAATAGGTACAATTTACATTGACGCGTCATGCCTTAGGTGGGAAGGACAGCAACC GGGGAAAGCTGCCATTGTGGAGAAGTTGTCTAGCCTTCTGTTCCAGAAAATCCAGTACAGCATCACA ACAGGACAATTAGCCCACACCAGATAGCTGCATCATCAGCATGGTTGTGGGTGAGCTTAAGGTAGAT GACCCCATCATCGGGTTCCACCAGATGTTCCTATTAAAGAATATCAGTGAAGCTTGGGTTTGCACCA ACATGTTCAGGCTTGCCCTGCTCACTTCGGCTGA Exons @	AAGATACAACCCGAATAGGTACAATTTACATTGACGCGTCATGCCTTAGGTGGGAAGGACA GGGGAAAGCTGCCATTGTGGAGAAGTTGTCTAGCCTTCTGTTCCAGAAAATCCAGTACAGG ACAGGACAATTAGCCCACACCAGATAGCTGCATCATCAGCATGGTTGTGGGTGAGCTTAAG GACCCCATCATCGGGTTCCCACCAGATGTTCCTATTAAAGAATATCAGTGAAGCTTGGGTT	001 ENST00000448540	384 No protein	-	Processed pseudoger	<u>e</u> -	TSL:NA GENCODE	bas
		ud sequence	Tanking sequence					
	Show/hide columns Filter					Filter		
Show/hide columns Filter No. Exon / Intron Start End Length Sequence Phase Filter	Showhide columns Filter No. Exon / Intron Start End Start End Length Sequence					Filter		
No. Exon / Intron Start End Start End Length Sequence	Show/hide columns Filter No. Exon / Intron Start End Length Sequence 5' upstream	intron Start End)	gccatagtgccagc			ga


Supplementary Figure S1: The information of IncRNA-NUTF2P3-001. (A) The description, location and sequence of NUTF2P3-001. (B) The exon of this transcript.




Supplementary Figure S2: The correlation between expression of lncR-NUTF2P3-001 and KRAS mRNA in different pancreatic tissues. (A) The correlations between NUTF2P3-001 and KRAS mRNA in pancreatic tissues. (B) The correlations between NUTF2P3-001 and KRAS mRNA level in noncancerous pancreatic tissue (NP). (C) The correlations between NUTF2P3-001 and KRAS mRNA level in pancreatic cancer (PC). (D) The correlations between NUTF2P3-001 and KRAS mRNA level in chronic pancreatitis (CP). The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).




Supplementary Figure S3: The siRNA sequences selection for lncRNA-NUTF2P3-001 and potential binding sites among lncRNA-NUTF2P3-001, miRNA-3923/miR-19b-3p and KRAS mRNA. (A) Three NUTF2P3-001-siRNA (50nM) and corresponding negative control (NC-siRNA) were designed and the most effective one (NUTF2P3-001-siRNA 1) was chosen to fulfill the following experiment. (B) Potential binding sites among NUTF2P3-001, miRNA-3923/miR-19b-3p and KRAS mRNA. All data were presented as means \pm SD of at least three independent experiments. The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).




Supplementary Figure S4: Overexpressed IncRNA-NUTF2P3-001 promoted viability, proliferation and invasive ability, while induced S phase arresting in pancreatic cancer cell. (A) 48 h post transfection, total RNA was extracted and qRT-PCR was used to identify the efficiency of transfection with pcDNA3.1 containing NUTF2P3-001 sequence (pcDNA-NUTF2P3-001) in pancreatic cancer cell. (B) 72 h post transfection, MTT assays were performed and the results demonstrated that pcDNA-NUTF2P3-001 remarkably promoted viability in pancreatic cancer cell. (C) The capacity of invasion was identified by Transwell assay 48 h after transfection. (D) The cell cycle distribution was measured by flow cytometry in PANC-1 cells. The results showed that pcDNA-NUTF2P3-001 induced compromised accumulation of S-phase. (E) pcDNA-NUTF2P3-001 obviously upregulated KRAS mRNA expression both in PANC-1 and BXPC-3 cell lines. KRAS and its downstream proteins in PANC-1 treated with pcDNA-NUTF2P3-001 were tested by western blot in PANC-1 cells. KRAS, p-AKT/AKT and p-ERK/ERK were significantly activated. Relative intensity value is marked. All data were presented as means \pm SD of at least three independent experiments. The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).



Supplementary Figure S5: The expression of miR-3923 in pancreatic tissues and correlations with lncRNA-NUTF2P3-001 or KRAS mRNA. (A) The expression of miR-3923 in 30 normal pancreas (NP), 10 chronic pancreatitis (CP) and 30 pancreatic cancer (PC) tissue samples was tested by qRT-PCR. Compared with normal pancreas (NP), miR-3923 was obviously decreased in pancreatic cancer (PC) specimens. (B) The correlations between miR-3923 and NUTF2P3-001 or KRAS expression in pancreatic tissues. The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).



Supplementary Figure S6: Overexpression of miR-3923 induced inhibition of proliferation and invasion, as well as S phase arresting in pancreatic cancer cell. (A) The effect of overexpressed miR-3923 on viability of pancreatic cancer cell was examined by MTT assay. The restore of miR-3923 (50nM) could remarkably prohibit the viability of pancreatic cancer cell. (B) The efficiency of LV-miR-3923 transfection was measured by qRT-PCR in pancreatic cancer cell. (C) Pancreatic cancer cell was transfected with LV-miR-3923 and LV-miR-NC respectively by 7 days' observation. Cells in LV-miR-NC group proliferated much faster than that of LV-miR-3923 group. (D) After treated with miR-3923 mimics (50 nM) or miR-NC (50 nM), the invasive ability of Pancreatic cancer cell was measured by Matrigel invasion assays. The invasion capacity of pancreatic cancer cell was significantly weakened due to overexpressed miR-3923. (E) Pancreatic cancer cell was treated as above, and cell cycle distribution and apoptosis were measured by flow cytometry. Obvious S-phase block was detected in miR-3923 treated PANC-1 cells. All data were presented as means \pm SD of at least three independent experiments. The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).



Supplementary Figure S7: SiRNA sequences selection for HIF-1 α . (A) Three HIF-1 α -siRNA and corresponding negative control (NC-siRNA) were designed and the most effective one (HIF-1 α -siRNA 1, 50 nM) for both PANC-1 and BXPC-3 was chosen to fulfill the following experiment. All data were presented as means \pm SD of at least three independent experiments. The *p*-value represents the comparison between groups (*p < 0.05, **p < 0.01).

Supplementary Table S1: SiRNA Sequences, cloning sequence and primers for NUTF2P3-001 cloning

SiRNA Targets	Sequences
NUTF2P3-001-siRNA1 sense	5'-GAGAUAAGCUGAUUUGGAA dTdT-3'
NUTF2P3-001-siRNA1 antisense	5'-dTdT CUCUAUUCGACUAAACCUU-3'
NUTF2P3-001-siRNA2 sense	5'-CGAAUAGGUACAAUUUACA dTdT -3'
NUTF2P3-001-siRNA2 antisense	5'-dTdT GCUUAUCCAUGUUAAAUGU-3'
NUTF2P3-001-siRNA3 sense	5'-CACAGGCACAGGACAAUUA dTdT-3'
NUTF2P3-001-siRNA3 antisense	5'-dTdT GUGUCCGUGUCCUGUUAAU-3'
HIF-1a-siRNA1 sense	5'-CUGAUGACCAGCAACUUGA dTdT -3'
HIF-1α-siRNA1 antisense	5'- dTdT GACUACUGGUCGUUGAACU-3'
HIF-1α-siRNA2 sense	5'- CUGAUGACCAGCAACUUGA dTdT-3'
HIF-1α-siRNA2 antisense	5'- dTdT GACUACUGGUCGUUGAACU-3'
HIF-1a-siRNA3 sense	5'- CAAUCAAGAAGUUGCAUUA dTdT-3'
HIF-1 <i>a</i> -siRNA3 antisense	5'- dTdT GUUAGUUCUUCAACGUAAU-3'

LncRNA-NUTF2P3-001 clone sequence in pcDNA3.1 XhoI / BamHI

Primers for cloning:

Sense: 5'- ACCG<u>CTCGAG</u>ATGGGAGATAAGCTGATTTGGAAG -3'

Antisense: 5'- CCATGGATCCTCAGCCGAAGTGAGCAGGGCAAG -3'